gg trend glp 1 patches Oral Treatment of Obesity by GLP-1 and Its Analogs Effective protective mechanisms of HO-1

56.6 years), had a higher proportion of white patients (70.5% vs

FDA Cracks Down on Deceptive Drug AdvertisingA Vital Reminder for Medical Device Industry The FDA has just launched a sweeping enforcement effort targeting misleading direct-to-consumer pharmaceutical advertising, issuing approximately 100 cease-and-desist letters and thousands of notifications aimed at ensuring transparency and accuracy in drug promotion

Icks A, Haastert B, Rathmann W, Wareham N

ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes

S.DiMarchiR.Mauvais-JarvisF

Weight Loss Effect of Glucagon-Like Peptide-1 Mimetics on Obese/Overweight Adults Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials